Correlation between Serum Endocan and HbA1c in Type 1 Diabetes Mellitus Patients

Catur Suci Sutrisnani, Sidarti Soehita Satjadibrata, Soebagijo Poegoeh Edijanto, Anik Widijanti, Haryudi Aji Cahyono


Endothelial dysfunction is a key mechanism in the pathogenesis of complications of cardiovascular disease in Diabetes Mellitus (DM) patients. One of the new biomarkers for inflammatory conditions and endothelial dysfunction is endocan. This study aimed to determine the correlation between endocan levels and HbA1c in type 1 DM patients. This study was an analytical observational study with a cross-sectional approach performed at the Dr. Saiful Anwar Hospital, Malang from May to August 2019. The research subjects were children aged 10-18 years with a diagnosis of type 1 DM who met the inclusion criteria. Students who underwent routine health checks participated as the control group. In both groups, serum endocan levels were measured using the ELISA method and HbA1c levels were measured by the HPLC method. Independent T-test analysis was used to determine the differences between both groups and the Pearson test was used to determine the correlation between serum endocan and HbA1c with SPSS version 23. In this study, there were 40 type 1 DM patients and 40 healthy controls with a mean age of 14.5 (3.16) years in the type 1 DM group and 14.7 (0.99) years in the healthy control group. There was a higher number of female subjects in both the type 1 DM group (57.5%) and the healthy control group (65%). The mean endocan level in the type 1 DM group was higher than the control group and was statistically significant with 1090.61 (150.84) pg/mL vs. 775.56 (8.91) pg/mL, p=0.000). The mean value for HbA1c levels in the type 1 DM group was also significantly higher compared to the control group 9.63 (2.22%) vs. 4.69 (0.251%), p <0.001), respectively. There was a significant positive correlation between endocan levels and HbA1c in DM patients (p=0.025, r=0.354). This study showed a correlation between serum endocan levels and HbA1c in patients with type 1 DM.


Type 1 diabetes mellitus, endocan, HbA1c, endothelial dysfunction

Full Text:



You W, Henneberg M. Type 1 diabetes prevalence

increasing globally and regionally: The role of natural

selection and life expectancy at birth. BMJ Open

Diabetes Research and Care, 2015; 000161: 1-2.

Craig ME, Jefferies C, Dabelea D, Balde N, Seth A,

Donaghue KC. Definition, epidemiology, and

classification of diabetes in children and adolescents.

ISPAD Clinical Practice Consensus Guidelines, 2018;

_035347: 3–7.

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH,

et al. Differentiation of diabetes by pathophysiology,

natural history, and prognosis. Diabetes, 2017; 66(2):


Alzubaidi M. Long-term complications of type 1

diabetes mellitus. University of Baghdad Engineering

Journal, 2018; 9(1): 21-24.

Kaufman FR. American Diabetes Association (ADA).

Medical management of type 1 diabetes. Virginia,

Amerika Serikat, 2019; 41(1): 137-141.

Rudiyanto A, Lindarto L, Pemayun TGD, Wisnu W.

Diabetes management, control, and complications in

patients with type 2 diabetes in Indonesia. Medical

Journal of Indonesia, 2019; 2(1): 1-2.

Ce GV, Rohde LE, Vargas da Silva AM, Ma´rcia Khaled

Pun˜ ales Coutinho, de Castro AC, Bertoluci MC.

Endothelial dysfunction is related to poor glycemic

control in adolescents with type 1 diabetes under 5

years of disease: Evidence of metabolic memory. J Clin

Endocrinol Metab, 2011; 96(5): 1493–1499.

Moreno B, de Faria AP, Ritter AMV, Yugar LBT,

Ferreira-Melo SE, et al. Glycated hemoglobin

correlates with arterial stiffness and endothelial

dysfunction in patients with resistant hypertension

and uncontrolled diabetes mellitus. J Clin Hypertens

(Greenwich), 2018; 20(5): 910-917.

Marcdante KJ, Kliegman RM. Diabetes mellitus. Nelson

essentials of pediatrics. Seventh Ed., Elsevier,

Philadelphia, 2015; 572-578.

Carrillo LM, Arciniegas E, Rojas H, Ramirez R.

Immunolocalization of endocan during the

endothelial mesenchymal transition process.

European Journal of Histochemistry, 2011; 55(2): e13.

Qiu CH, FuQ, Sui J, Zhang Q. Analysis of serum

endothelial cell-specific molecule I (endocan) in type 2

diabetes mellitus with acute ST-segment elevation

myocardial infarction and its correlation: A pilot study.

Epub, 2017; 68(I): 74-78.

Balta S, Mikhailidis DP, Demirkol S, Ozturk C. Endocan:

A novel inflammatory in cardiovascular disease?.

Atherosclerosis, Elsevier, 2015; 243: 339-343.

Zeng L, Dang Tan A, Schunkert H. Genetics link

between transforming growth factor β Pathway and

coronary disease. Atherosclerosis, 2016; 08: 029.

Lv Y, Zhang Y, Shi W, Liu J, Li Y, et al. The association

between endocan level s and subclinical

atherosclerosis in patients with type 2 diabetes

mellitus. Am J Med Sci, 2017; 353(5): 433-438.

Arman Y, Murat Kose, Timur Selcuk Akpinar, Samim

Emet. Effect of glycemic regulation on endocan levels

in patients with diabetes: A preliminary study.

Angiology, 2015; 67(3): 1-9.

Rad MP, Farrokh D, Vikli R, Omidbakhsh, Muhammadi

M. The association between carotid intima-media

thickness and the duration of type 1 diabetes in

children. Iran J Pediatr, 2014; 24(3): 249-254.

Márcia A, Sequeira I, Vasconcelos DF. Endothelial

dysfunction in children with type 1 diabetes mellitus.

Arch. Endocrinol. Metab, 2017; 61: 5.

Lespagnol E, Daucchet L, Chaouch MP, Balestra C,

Barthoin S. Early endothelial dysfunction in type 1

diabetes is accompanied by an impairment of vascular

smooth muscle function: A meta-analysis. Front.

Indocrinol, 2020; 00203.

De Ferranti, Fonseca V, Golden SH, Marx N. Type 1

diabetes and cardiovascular disease: Advances and

need. American Heart Association, 2020; 127:


Mona HM, Sahar SA, Hend SM, Nanees AA.

Dyslipidemia in type 1 diabetes mellitus: Relation to

diabetes duration, glycemic control, body habitus,

dietary intake and other epidemiological risk factors.

Egyptian Pediatric Association Gazette, 2015; 63(2):


Fusaro MFGS, Zanini JLSS, Silva IV. Increased carotid

intima-media thickness in Brazilian adolescents with

type 1 diabetes mellitus. Diabetol Metab Syndr, 2016; 8: 74.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.